The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -63.82 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -8.06 — no flag raisedOK
- Earnings quality 79/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as Insight Molecular Diagnostics Inc. reports it. History and quarterly detail are in the app.
- Laboratory Services$4.0M
- Kitted Products$24K
Leadership changes
From Insight Molecular Diagnostics Inc.'s own filings, the day they're filed.
- Andrea James · Chief Financial Officer · appointmenteff. 2024-06-17
- Axon Enterprise · President · appointment
- Base Salary · departure
Latest filings
- 8-K · Company announcement2026-06-17
- 8-K · Company announcement2026-05-13
- 10-Q · Quarterly report2026-05-13
- 8-K · Company announcement2026-04-30
- DEF 14A · Annual proxy (pay & governance)2026-04-30
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Insight Molecular Diagnostics Inc., every answer cited🔒
- The Intelligence Brief — added when Insight Molecular Diagnostics Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.